

January 14, 2022

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051.

Scrip code: 512529

Symbol: SEQUENT

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) - Change in Managing Director and Chief Executive Officer of the Company.

Pursuant to Regulation 30 read with Part A, Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**LODR Regulations**”), we wish to inform you that the Board of Directors of the Company has taken on record/approved the following changes in the composition of the Board of Directors at its meeting held on January 14, 2022:

Name of Director	Resignation/Appointment
Mr. Manish Gupta (DIN: 06805265)	Resigned as a Managing Director and Chief Executive Officer (MD & CEO) of the Company with effect from April 10, 2022.
Mr. Rajaram Narayanan (DIN: 02977405)	Appointed as MD & CEO of the Company for a period of 5 years, with effect from April 11, 2022. The appointment is subject to the approval of shareholders of the Company, which shall be sought separately.

Mr. Rajaram Narayanan is not debarred from holding office of director by virtue of any order by the Securities and Exchange Board of India (“**SEBI**”) or any other such authority.

Please note that the relevant details regarding the change in directors required to be disclosed under the SEBI circular CIR/CFD/CMD/4/2015 dated September 9, 2015, are enclosed herewith in the annexure to this letter.

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No.E7, Road No. 22, Wagle Industrial Area,
Thane(W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>



We request you to take the above on record.

Yours faithfully,
For **Sequent Scientific Limited**

Krunal Shah
Company Secretary & Compliance Officer



SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No.E7, Road No. 22, Wagle Industrial Area,
Thane(W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

ANNEXURE I

Name of the Director	Mr. Manish Gupta (DIN: 06805265)
Reason for change, viz, resignation	Mr. Manish has tendered his resignation as Managing Director and CEO of the Company with effect from close of business hours on April 10, 2022 to pursue other opportunities.
Date of cessation	The resignation is effective from close of business hours on April 10, 2022.
Brief profile	Not Applicable
Disclosure of relationship between directors	Not Applicable

* Mr. Manish Gupta will continue to serve as a strategic advisor to the Company until July 2022 post cessation of directorship.

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No.E7, Road No. 22, Wagle Industrial Area, Thane(W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

Name of the Director	Mr. Rajaram Narayanan (DIN: 02977405)
Reason for change, viz, appointment	<p>The Board of Directors of the Company, pursuant to the recommendation by the Nomination and Remuneration Committee, approved the appointment of Mr. Rajaram Narayanan as the Managing Director and Chief Executive Officer of the Company for a period of 5 years with effect from April 11, 2022, subject to the approval of the shareholders of the Company.</p> <p>Mr. Narayanan, who has served in senior leadership roles across the pharmaceutical, consumer goods and services industries, succeeds Mr. Manish Gupta who will be stepping down effective April 10, 2022 after serving as MD and CEO of the Company for past eight years</p>
Date of appointment	The appointment is effective from April 11, 2022
Term of appointment	Appointed for a period of 5 (Five) years from the date of appointment
Brief profile	With over 25 years of experience, Mr. Narayanan has a strong track record of leading revenue and profitability growth across multiple industries including pharmaceuticals. He joins from Sanofi India Limited, where he was the Managing Director and Country Chair for India. At Sanofi, he led the strategic reorientation of its India business operations, resulting in accelerated growth in key therapies and significant transformation of Sanofi's market operations. Before this, he was Chief Marketing Officer at Airtel, India's leading telecommunications company. Mr. Narayanan started his career at Hindustan Unilever Ltd., where he held various

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No.E7, Road No. 22, Wagle Industrial Area, Thane(W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

	<p>leadership roles in India and other Asian markets for over 18 years, building and managing many iconic consumer brands.</p> <p>Mr. Narayanan holds a Degree in BE (Hons)-Electrical & Electronics from Birla Institute of Technology and Science, Pilani, MBA from Indian Institute of Foreign Trade, New Delhi and Advanced Management Program from Harvard Business School, Boston, USA.</p>
<p>Disclosure of relationship between directors</p>	<p>Mr. Rajaram Narayanan is not related to any Director of the Company.</p>

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No.E7, Road No. 22, Wagle Industrial Area, Thane(W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>